Literature DB >> 23957913

Recent advances of immunohistochemistry for diagnosis of renal tumors.

Naoto Kuroda1, Azusa Tanaka, Chisato Ohe, Yoji Nagashima.   

Abstract

The recent classification of renal tumors has been proposed according to genetic characteristics as well as morphological difference. In this review, we summarize the immunohistochemical characteristics of each entity of renal tumors. Regarding translocation renal cell carcinoma (RCC), TFE3, TFEB and ALK protein expression is crucial in establishing the diagnosis of Xp11.2 RCC, renal carcinoma with t(6;11)(p21;q12), and renal carcinoma with ALK rearrangement, respectively. In dialysis-related RCC, neoplastic cells of acquired cystic disease-associated RCC are positive for alpha-methylacyl-CoA racemase (AMACR), but negative for cytokeratin (CK) 7, whereas clear cell papillary RCC shows the inverse pattern. The diffuse positivity for carbonic anhydrase 9 (CA9) is diagnostic for clear cell RCC. Co-expression of CK7 and CA9 is characteristic of multilocular cystic RCC. CK7 and AMACR are excellent markers for papillary RCC and mucinous tubular and spindle cell carcinoma. CD82 and epithelial-related antigen (MOC31) may be helpful in the distinction between chromophobe RCC and renal oncocytoma. WT1 and CD57 highlights the diagnosis of metanephric adenoma. The combined panel of PAX2 and PAX8 may be useful in the diagnosis of metastatic RCC.
© 2013 The Authors. Pathology International © 2013 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  ALK; TFE3; TFEB; immunohistochemistry; renal tumors

Mesh:

Substances:

Year:  2013        PMID: 23957913     DOI: 10.1111/pin.12080

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  15 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  The significance of TIMD4 expression in clear cell renal cell carcinoma.

Authors:  Hiromu Yano; Takanobu Motoshima; Chaoya Ma; Cheng Pan; Sohsuke Yamada; Toshiyuki Nakayama; Shohei Kitada; Naohiro Fujimoto; Tomomi Kamba; Motohiro Takeya; Yoshihiro Komohara
Journal:  Med Mol Morphol       Date:  2017-06-19       Impact factor: 2.309

Review 3.  Solitary fibrous tumor of the kidney with focus on clinical and pathobiological aspects.

Authors:  Naoto Kuroda; Chisato Ohe; Noriko Sakaida; Yoshiko Uemura; Keiji Inoue; Yoji Nagashima; Ondrej Hes; Michal Michal
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

4.  TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.

Authors:  Masaya Baba; Mitsuko Furuya; Takanobu Motoshima; Martin Lang; Shintaro Funasaki; Wenjuan Ma; Hong-Wei Sun; Hisashi Hasumi; Ying Huang; Ikuma Kato; Tsuyoshi Kadomatsu; Yorifumi Satou; Nicole Morris; Baktiar O Karim; Lilia Ileva; Joseph D Kalen; Luh Ade Wilan Krisna; Yukiko Hasumi; Aiko Sugiyama; Ryoma Kurahashi; Koshiro Nishimoto; Masafumi Oyama; Yoji Nagashima; Naoto Kuroda; Kimi Araki; Masatoshi Eto; Masahiro Yao; Tomomi Kamba; Toshio Suda; Yuichi Oike; Laura S Schmidt; W Marston Linehan
Journal:  Mol Cancer Res       Date:  2019-05-01       Impact factor: 5.852

Review 5.  Clear cell papillary renal cell carcinoma: a review.

Authors:  Naoto Kuroda; Chisato Ohe; Fumi Kawakami; Shuji Mikami; Mitsuko Furuya; Keiko Matsuura; Masatsugu Moriyama; Yoji Nagashima; Ming Zhou; Fredrik Petersson; José I López; Ondrej Hes; Michal Michal; Mahul B Amin
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Renal collision tumour of papillary cell carcinoma and chromophobe cell carcinoma with sarcomatoid transformation: A case report and review of the literature.

Authors:  Zhiqiang Zhang; Jie Min; Dexin Yu; Haoqiang Shi; Dongdong Xie
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

7.  A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.

Authors:  Aiko Kurisaki-Arakawa; Tsuyoshi Saito; Michiko Takahashi; Keiko Mitani; Yuki Fukumura; Yoji Nagashima; Pedrum Argani; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

8.  A case of tubulocystic carcinoma of the kidney with aggressive features.

Authors:  Yoko Maeda; Keisuke Goto; Yukiko Honda; Naoto Kuroda; Kazuhiro Sentani; Wataru Yasui; Tetsutaro Hayashi; Jun Teishima; Akio Matsubara; Yuko Nakamura; Naoyuki Toyota; Makoto Iida; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2016-02-01       Impact factor: 2.374

Review 9.  Eosinophilic cytoplasmic inclusions in type 2 papillary renal cell carcinoma.

Authors:  M Ungari; M Trombatore; G Ferrero; M D Gusolfino; L Manotti; G Tanzi; E Varotti; R Bertoni
Journal:  Pathologica       Date:  2019-12

10.  Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.

Authors:  Tetsuya Danno; Shohei Iwata; Fusako Niimi; Sachi Honda; Haruka Okada; Takeshi Azuma
Journal:  Case Rep Urol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.